Stifel lowered the firm’s price target on DocGo to $11 from $12 and keeps a Buy rating on the shares. Over the past few weeks, New York City paid the company approximately $50M under the Housing Preservation & Development contract, the analyst tells investors. While contract controversy may continue in the short term, Stifel remains optimistic that the company signing other mobile health contracts will affirm its secular prospects and drive multiple expansion.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DCGO:
- DocGo Announces $36 Million Share Buyback Program
- DocGo Amends Credit Agreement for $40M Share Buyback
- DocGo announces new $36M share repurchase program
- DocGo provides additional information pertaining to short seller report
- DocGo says short seller incorrect to claim dramatic decline in 2024 revenue